trending Market Intelligence /marketintelligence/en/news-insights/trending/ihk8batcwu2zagx06njvrg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *

* Required

In this list

Bristol-Myers Squibb nabs global rights to PsiOxus' solid tumors treatment

Street Talk Episode 51 - Goldman Talks Libor Transition, Recent SOFR Volatility

#ChangePays: Although Still Underrepresented, Women in the C-Suite are Driving Profitability

Cable Nets For Kids Enjoy Wide Carriage On Skinny Bundles

Energy

Power Forecast Briefing: Fleet Transformation, Under-Powered Markets, and Green Energy in 2018


Bristol-Myers Squibb nabs global rights to PsiOxus' solid tumors treatment

Bristol-Myers Squibb Co. secured exclusive worldwide rights to PsiOxus Therapeutics Ltd.'s NG-348, a preclinical stage oncolytic virus for the potential treatment of solid tumors.

The deal is subject to clearance under the Hart-Scott-Rodino Act.

Bristol-Myers will make a $50 million up-front payment to PsiOxus for the rights and will be solely responsible for global clinical development and commercialization activities for the treatment. The company will also provide PsiOxus funding to support activities related to the preclinical development of the therapy.

PsiOxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sales.

Oncolytic virus therapy utilizes modified viruses such as the adenovirus that selectively replicate within tumor cells and not within normal tissue. Such viruses stimulate an inflammatory response in the tumor microenvironment, resulting in the accumulation of tumor infiltrating lymphocytes.